RIGL Stock Summary and Trading Ideas (Rigel Pharmaceuticals | NASDAQ:RIGL)

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Rigel Pharmaceuticals trades on the NASDAQ stock market under the symbol RIGL.

As of September 11, 2026, RIGL stock price declined to $47.24 with 179,567 million shares trading.

RIGL has a beta of 1.10, meaning it tends to be more sensitive to market movements. RIGL has a correlation of 0.05 to the broad based SPY ETF.

RIGL has a market cap of $874.04 million. This is considered a Small Cap stock.

Last quarter Rigel Pharmaceuticals reported $79 million in Revenue and $.88 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.71.

In the last 3 years, RIGL traded as high as $52.24 and as low as $7.12.

The top ETF exchange traded funds that RIGL belongs to (by Net Assets): AVUV, XBI, VTI, VXF, SCHA.

RIGL has outperformed the market in the last year with a price return of +29.5% while the SPY ETF gained +18.3%. RIGL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +52.8% and +0.8%, respectively, while the SPY returned +5.6% and -0.9%, respectively.

RIGL support price is $45.92 and resistance is $48.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RIGL shares will trade within this expected range on the day.